Share tips of the week
MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
Six to buy
Britvic
(The Sunday Telegraph) A new wave of lockdowns once again puts the focus on shares offering a strong market position, famous brands and solid balance sheets. Britvic, the maker of J2O and Fruit Shoot, fits the bill. It is also Pepsi’s long-term UK bottling partner. Around 40% of sales come from pubs and restaurants, so revenue is down this year, but consumers have been buying more drinks in supermarkets, which has helped it dodge the worst. On 14 times forecast earnings there is scope for the shares to fizz higher in the long term. Buy. 746p
Cake Box Holdings
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
(Interactive Investor) This franchiser of cream-cake shops is likely to see strong demand as a “Covid winter” drives us all towards comfort foods. Recent trading updates have been encouraging, with online sales up by 74% over the three months to the end of August. New franchises are continuing to open and disruption elsewhere in the hospitality industry will give new shops the “pick of talent… Cake may be naughty but [it] is irresistibly nice.” A “speculative” buy. 176p
De La Rue
(The Times) The turnaround at one of the London market’s oldest listed businesses is gathering pace under a new management team. The Serious Fraud Office ended a probe into South Sudan-linked corruption in June, removing one significant risk. A £100m issue of new shares over the summer helps shore up the balance sheet and will fund investment in polymer banknote production and the authentication operation. Growing demand for polymer notes and the World Health Organisation’s tobacco tax stamp scheme should ensure a steady pipeline of business. Buy. 144p
Experian
(Shares) This credit checker has a vast database of “163 million businesses and 1.3 billion consumer-credit history records”. The company ticks all the quality boxes, with high cash generation, market and sector-beating margins and resilient growth, including during the pandemic. There are only two other players in this sector – Equifax and TransUnion – and tight data regulation and the time it takes to build up a database keeps new competitors out. On a forward price/earnings ratio of 37.1 the shares are far from cheap, but it is worth paying up for one of the world’s “safest growth compounders”. 3,069p
Hikma Pharmaceuticals
(Investors Chronicle) This multinational supplier of generic medicines is well-placed to profit from an ageing population. Chronic conditions and associated drug shortages are on the rise across the developed world, boosting demand for alternatives to pricey brand-name treatments. That should see global generic sales top $100bn by the middle of the decade, up from $70bn last year. Operating across more than 50 countries, Hikma offers diversified revenue and invests continuously in its pipeline to offer more complex and profitable treatments. Buy. 2,685p
Inspiration Healthcare
(The Mail on Sunday) This Aim-listed business supplies medical technology used in critical care to customers in 75 countries. It has a particular reputation for neonatal care and also stepped in earlier this year to help import ventilators during the first wave of the pandemic. In Britain, “virtually every hospital uses at least one of its products”. Revenues should double in the current year and management is hoping to triple sales to £100m over the next five to seven years. Inspiration Healthcare recently paid out its first dividend and there should be more to come. Buy. 66p
...and the rest
The Daily Telegraph
Ventilation specialist Volution Group has been on the acquisition trail in what remains a fragmented market. The pandemic has put renewed focus on the importance of good ventilation, so buy (197p).
Investors Chronicle
Buoyant global markets in iron ore, copper and gold make engineer Weir Group’s decision to refocus on the mining industry look astute. There could be long-term upside for metals as emerging economies get going again, so keep buying the shares (1,629p).
The Mail on Sunday
Disease testing specialist EKF Diagnostics is likely to see profits more than double this year. A maiden dividend is due in December and the long-term outlook is equally auspicious, so keep buying (59p).
Shares
IP Group, which partners with British universities to bring new science businesses to life, recently sold out of an alternative-energy supplier for a tidy profit. The disposal could prove “the first of many”, so buy (83p). Shares in global- equity investor Mid Wynd have been trading near all-time highs thanks to the US tech rally, but the portfolio also offers exposure to less modish Asian growth stocks. “Keep buying” (679p).
The Times
Nike’s strong brand and online operation have helped it thrive through the crisis but on a price/earnings ratio of 76 the shares are even more expensive than those of big tech. Avoid ($129). Central European drinks seller Stock Spirits Group has seen sales continue to rise despite lockdown and the shares are on a big discount to the sector. Buy (237p).
-
British Airways revamps Avios scheme bringing down flight prices to £1
With the new Avios part-payments scheme you can now bag a British Airways flight for as little as £1
By Oojal Dhanjal Published
-
RBS to close a fifth of branches
Royal Bank of Scotland plans to shut 18 branches across Scotland, resulting in the loss of 105 jobs. We have the full list of closures.
By Ruth Emery Published
-
The industry at the heart of global technology
The semiconductor industry powers key trends such as artificial intelligence, says Rupert Hargreaves
By Rupert Hargreaves Published
-
Three emerging Asian markets to invest in
Professional investor Chetan Sehgal of Templeton Emerging Markets Investment Trust tells us where he’d put his money
By Chetan Sehgal Published
-
What to consider before investing in small-cap indexes
Small-cap index trackers show why your choice of benchmark can make a large difference to long-term returns
By Cris Sholto Heaton Published
-
Why space investments are the way to go for investors
Space investments will change our world beyond recognition, UK investors should take note
By Merryn Somerset Webb Published
-
Time to tap into Africa’s mobile money boom
Favourable demographics have put Africa on the path to growth when it comes to mobile money and digital banking
By Rupert Hargreaves Published
-
M&S is back in fashion: but how long can this success last?
M&S has exceeded expectations in the past few years, but can it keep up the momentum?
By Rupert Hargreaves Published
-
The end of China’s boom
Like the US, China too got fat on fake money. Now, China's doom is not far away.
By Bill Bonner Published
-
Magic mushrooms — an investment boom or doom?
Investing in these promising medical developments might see you embark on the trip of a lifetime.
By Bruce Packard Published